Simultaneous Determination of Cholecalciferol and 25- Hydroxycholecalceferol in Lipid-based Self-nanoemulsifying formulations and Marketed Product Vi-de 3® by UHPLC-UV

Author(s): Ibrahim Aljuffali, Fahad Almarri, A. F. M. Motiur Rahman, Fars Kaed Alanazi, Musaed Alkholief, Mohsin Kazi*.

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The purpose of the current study was to develop a selective, precise, fast economical and advanced reverse phase ultra-high-performance liquid chromatography (UHPLC UV) method and validate it for the simultaneous estimation of cholecalciferol and its analogue 25- hydroxycholecalciferol in lipid-based self-nano emulsifying formulation (SNEDDS).

Methods: The chromatographic separation was simply performed on a Dionex® UHPLC systems (Ultimate 3000, Thermo scientific) by using HSS C18 (2.1x50 mm, 1.8 µm) analytical column. The elution was carried out isocratically with the mobile phase consisting of acetonitrile and methanol in the ratio of 50:50 %v/v with a flow rate of 0.4 ml/min, followed by the UV detection at 265 nm. The injection volume was 1µl and the column temperature was maintained at 45°C. FDA regulatory guidelines were used to develop and validate the method.

Results: The current developed UHPLC-UV method was found to be rapid (run time 2 min), and selective with the high resolution of cholecalciferol and 25-hydroxycholecalciferol (RT=0.530 min & 1.360 min) from different lipid matrices. The method was highly sensitive (Limit of Detection and Lower Limit of Quantification were 0.13 ppm & 0.51ppm, and 0.15 ppm & 0.54 ppm, respectively). The linearity, accuracy and precision were determined as suitable over the concentration range of 0.5-50.0 ppm for both the analytes.

Conclusion: The proposed UHPLC-UV method can be used for the determination of cholecalciferol and 25-hydroxycholecalciferol in SNEDDS and marketed Vi-De 3® as pure forms (intact) with no interference of excipients or drug-related substances.

Keywords: Cholecalciferol, 25-hydroxycholecalciferol, UHPLC, lipid-based formulation, method validation, simultaneous analysis.

[1]
Ozturk, B.; Argin, S.; Ozilgen, M.; McClements, D.J. Nanoemulsion delivery systems for oil-soluble vitamins: Influence of carrier oil type on lipid digestion and vitamin D3 bioaccessibility. Food Chem., 2015, 187, 499-506.
[2]
Coelho, I.M.; Andrade, L.D.; Saldanha, L.; Diniz, E.T.; Griz, L.; Bandeira, F. Bioavailability of vitamin D3 in non-oily capsules: the role of formulated compounds and implications for intermittent replacement. Arquivos brasileiros de endocrinologia e metabologia, 2010, 54(2), 239-243.
[3]
Hogler, W. Complications of vitamin D deficiency from the foetus to the infant: One cause, one prevention, but who’s responsibility? Best practice & research. J. Clin. Endocrinol. Metab., 2015, 29(3), 385-398.
[4]
Almouazen, E.; Bourgeois, S.; Jordheim, L.P.; Fessi, H.; Briancon, S. Nano-encapsulation of vitamin D3 active metabolites for application in chemotherapy: formulation study and in vitro evaluation. Pharm. Res., 2013, 30(4), 1137-1146.
[5]
Guttoff, M.; Saberi, A.H.; McClements, D.J. Formation of vitamin D nanoemulsion-based delivery systems by spontaneous emulsification: factors affecting particle size and stability. Food Chem., 2015, 171, 117-122.
[6]
Ozturk, B.; Argin, S.; Ozilgen, M.; McClements, D.J. Formation and stabilization of nanoemulsion-based vitamin E delivery systems using natural biopolymers: Whey protein isolate and gum arabic. Food Chem., 2015, 188, 256-263.
[7]
Bartolucci, G.; Giocaliere, E.; Boscaro, F.; Vannacci, A.; Gallo, E.; Pieraccini, G.; Moneti, G. Vitamin D3 quantification in a cod liver oil-based supplement. J. Pharm. Biomed. Anal., 2011, 55(1), 64-70.
[8]
Almarri, F.; Haq, N.; Alanazi, F.K.; Mohsin, K.; Alsarra, I.A.; Aleanizy, F.S.; Shakeel, F. Solubility and thermodynamic function of vitamin D3 in different mono solvents. J. Molecul. Liquids, 2017, 229, 477-481.
[9]
Kazi, M.; Shariare, M.H.; Al-bgomi, M.; Hussain, M.D.; Alanazi, F.K. Simultaneous determination of Curcumin (Cur) and Thymoquinone (THQ) in lipid based self-nanoemulsifying systems and its application to the commercial product using UHPLC-UV-Vis spectrophotometer. Curr. Pharm. Anal., 2017, 13, 1-9.
[10]
Kazi, M.; Al-Qarni, H.; Alanazi, F.K. Development of oral solid self-emulsifying lipid formulations of risperidone with improved in vitro dissolution and digestion. Eur. J. Pharm. Biopharm., 2017, 114, 239-249.
[11]
Siddiqui, M.R.A.; AlOthman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: a review. Arab. J. Chem., 2017, 10, S1409-S1421.
[12]
AlOthman, Z.A.; Rahman, N.; Siddiqui, M.R. Review on pharmaceutical impurities, stability studies and degradation products: an analytical approach. Rev. Adv. Sci. Eng., 2013, 2, 155-166.
[13]
Rahman, N.; Azmi, S.N.H.; Wu, H.F. The importance of impurity analysis in pharmaceutical products: an integrated approach. Accredit. Qual. Assur., 2006, 11, 69-74.
[14]
Wang, Z.; Senn, T.; Kalhorn, T.; Zheng, X.E.; Zheng, S.; Davis, C.L.; Hebert, M.F.; Lin, Y.S.; Thummel, K.E. Simultaneous measurement of plasma vitamin D (3) metabolites, including 4beta, 25-dihydroxyvitamin D (3), using liquid chromatography-tandem mass spectrometry. Anal. Biochem., 2011, 418(1), 126-133.
[15]
Hall, W.L.; Jeanes, Y.M.; Pugh, J.; Lodge, J.K. Development of a liquid chromatographic time-of-flight mass spectrometric method for the determination of unlabelled and deuterium-labelled alpha-tocopherol in blood components. Rapid Commun. Mass Sp., 2003, 17(24), 2797-2803.
[16]
Bunch, D.R.; Miller, A.Y.; Wang, S.H. Development and validation of a liquid chromatography-tandem mass spectrometry assay for serum 25-hydroxyvitamin D2/D3 using a turbulent flow online extraction technology. Clin. Chem. Lab. Med., 2009, 47(12), 1565-1572.
[17]
Kobold, U. Approaches to measurement of Vitamin D concentrations - Mass spectrometry. Scand. J. Clin. Lab. Invest., 2012, 72, 54-59.
[18]
Q2A, I., (R1), Validation of Analytical Procedures: Text and Methodology International Conference on Harmonization, Geneva, Switzerland, 2005.
[19]
Yu, L.; Xiang, B.; Zhan, Y. A simple high-performance liquid chromatographic method for the determination of acyclovir in human plasma and application to a pharmacokinetic study. Arzneimittelforschung, 2008, 58(4), 199-202.
[20]
ICH, ICH Steering Committee, ICH Harmonized Tripartite Guidlines, Q1A (R2), Stability testing of new drug subtances and products. 2003.
[21]
Mulholland, M.; Hibbert, D.B. Linearity and the limitations of least squares calibration. J. Chromatography. A, 1997, 762(1-2), 73-82.
[22]
Mohsin, K. Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion. AAPS PharmSciTech, 2012, 13(2), 637-646.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [100 - 109]
Pages: 10
DOI: 10.2174/1573412915666190612141228

Article Metrics

PDF: 3
HTML: 2

Special-new-year-discount